These findings highlight the potential of targeting this axis, either at the FGF12-YB1 interface, through YB1 inhibition, or via lncRNA disruption, as a promising strategy to attenuate survival signaling in advanced PCa. The gene discussed is FGF12; the disease is posterior cortical atrophy.